Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baker Hughes Co (BKR) vs Incyte Corporation (INCY) Price & Performance

Baker Hughes CoTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Baker Hughes Co vs Incyte Corporation — how do they compare? Baker Hughes Co trades at $64.74 (market cap $64.34B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Baker Hughes Co is far larger — about 2.6× Incyte Corporation's market cap, and Baker Hughes Co pays a 1.42% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

BKRINCY
Market Cap
$64.34B$24.54B
Sector
EnergyHealth
52-Week High
$69.67$129.93
52-Week Low
$42.51$81.61
Enterprise Value
$64.86B$20.04B
Dividend Yield
1.42%

Returns comparison

Trailing returns across standard periods

About Baker Hughes Co

Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.

Read more on BKR

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY